Use of Navakarshik ghanvati in vatarakta.

Randomised open controlled clinical study to evaluate the efficacy of Navakarshik ghanvati in vatarakta w s r to Gout - Nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/081333

Enrollment

Registered

2025-02-25

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M109- Gout, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patient presenting Toda Shotha and Sthabdhata in relation to Parvasandhi Patients having serum uric acid level more than 7mg/dl in male and more than 6mg/ dl in female.

Exclusion criteria

Exclusion criteria: Known case of Amavata Sandhigatvata SLE Patient on chronic use of NSAIDS and steroidal inflammatorydrugs Pregnancy Lactating mothers Patients prediagnosed with autoimmune diseases of joint Patients with severe toxicity, ulceration, progressive gangrenous changes, and suffering from diseases of immunological basis. Patients associated with metabolic disorders and systemic diseases.

Design outcomes

Primary

Measure	Time frame
To study the efficacy of Nawakarshika ghanvati in vatarakta.Timepoint: 30 days	—

Secondary

Measure	Time frame
To reduce the signs and symptoms of Vatarakta. To assess the improvement by signs, symptoms and gradation of assessment criteria. To study etiopathology & clinical manifestation of Vatarakta. To improve quality of life and reduce discomfort of Patient. To achieve the outcome of study in 1 month.Timepoint: 30 days	—

Countries

India

Contacts

Public ContactDr Krishna Punasing Pawar

Yashwant Ayurvedic College Post Graduate Training and Research Centre Kodoli

drdipaliswamis@gmail.com9960003947

Outcome results